A phase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenance - TOTA

YSARC0 个研究点目标入组 70 人开始时间: 2018年2月1日最近更新: 2021年6月21日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 70

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- Males and females of 18 years to 80 years of age
•- Understand and voluntarily sign an informed consent document prior to any study related assessment or procedure
•- Patients able to adhere to the study visit schedule and protocol requirements
•- Patients with histologically proven, CD30 positive (at least 5% of cells
•according to local examination) peripheral T-cell lymphoma (PTCL) according to the 2016 WHO classification for whom gemcitabine treatment is expected. A biopsy at relapse is highly recommended
•- Patients who have evidence of relapsed disease after at least one line (and no more than three lines) of treatment or who were refractory to a first or subsequent line of treatment
•- Patients with Ann Arbor stage I – IV
•- Patients with ECOG performance status of 0 - 2
•- Patients with at least one measurable disease, i.e. one nodal or extra-nodal lesion of 1.5 cm or more
•- Negative pregnancy test for females of childbearing potential (FCBP)
•- Female patients of child bearing potential must use an effective method of birth control (i.e. hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) during treatment period and 6 months thereafter
•- Males must use an effective method of birth control during treatment period and 6 months thereafter
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 60
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

排除标准

•- Any significant medical condition or laboratory abnormality unrelated to PTCL, or psychiatric illness that would prevent the patient from participating in the study and from signing the informed consent form
•- Any condition that confounds the ability to interpret data from the study
•- Other types of lymphomas, e.g. B-cell lymphoma
•- Central nervous system and/or meningeal involvement by PTCL
•- Signs or symptoms of Progressive Multifocal Leukoencephalopathy
•- Preexistent peripheral neuropathy = grade 2, whatever the cause
•- Contraindication to any drug contained in the chemotherapy regimen
•- Subjects with HIV or HTLV1 positivity
•- Subjects with active hepatitis B or C. Chronic carriers of hepatitis B without HBV DNA positive blood are eligible. Subjects with non-active hepatitis C (with normal transaminases) are eligible
•- Chronic or acute, clinically significant, untreated bacterial, viral or fungal infection
•- Any of the following laboratory abnormalities:
•a. Absolute neutrophil count (ANC) < 1500 cells/mm3 (1.5 x 109/L);
•b. Platelet count <75,000/mm3 (75 x 109/L);
•c. Serum SGOT/AST or SGPT/ALT = 3.0 x upper limit of normal (ULN).
•SGOT/AST or SGPT/ALT may be elevated up to 5 x ULN if their elevation can be ascribed to the presence of hematologic/solid tumor in the liver
•d. Serum total bilirubin > 1.5 x ULN
•e. Serum lipase level > 2 x ULN
•f. Serum creatinine > 2.0 mg/dL and/or creatinine clearance or calculated creatinine clearance < 40 mL/minute
•g. Hemoglobin < 8g/dL
•- Active malignancies other than PTCL requiring systemic treatment
•- Previous treatment with brentuximab vedotin
•- Previous treatment with gemcitabine
•- Pregnant or lactating females or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study
•- Known history of any of the following cardiovascular conditions:
•o Myocardial infarction within 2 years of enrollment
•o New York Heart Association (NYHA) Class III or IV heart failure
•o Evidence of current uncontrolled cardiovascular conditions,
•including cardiac arrhythmias, congestive heart failure (CHF),
•angina, or electrocardiographic evidence of acute ischemia or
•active conduction system abnormalities
•o Recent evidence (within 6 months before first dose of study drug) of
•a left-ventricular ejection fraction <50%
•- Patients that have not completed any prior treatment chemotherapy and/or other investigational agents within at least 5 half-lives of last dose of that prior treatment
•- Diagnosed or treated for another malignancy within 3 years before the first dose or previously diagnosed with another malignancy and have evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
•- Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin

研究者

发起方

YSARC

相似试验

进行中（未招募）

1 期

Phase II study on the role of brentuximab vedotin as single agent in the treatment of relapsed/refractory CD30 positive peripheral T cell lymphoma (PTCL) patientsRELAPSED/REFRACTORY CD30 POSITIVE PERIPHERAL T CELL LYMPHOMA (PTCL)

EUCTR2013-003946-17-ITFondazione Italiana Linfomi ONLUS25

进行中（未招募）

1 期

EUCTR2019-003982-17-ITSEATTLE GENETICS, INC.100

进行中（未招募）

1 期

Study of brentuximab vedotin combined with RCHOP or RCHP for front-line treatment of patients with diffuse large B-cell lymphoma (DLBCL)Diffuse large B-cell lymphoma (DLBCL)MedDRA version: 18.1Level: LLTClassification code 10012820Term: Diffuse large B-cell lymphoma NOSSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000004864

EUCTR2015-004741-54-ESSeattle Genetics, Inc.50

进行中（未招募）

1 期

Study of brentuximab vedotin combined with RCHOP or RCHP for front-line treatment of patients with diffuse large B-cell lymphoma (DLBCL)

EUCTR2015-004741-54-CZSeattle Genetics, Inc.50

进行中（未招募）

1 期

Study of brentuximab vedotin combined with RCHOP or RCHP for front-line treatment of patients with diffuse large B-cell lymphoma (DLBCL)Diffuse large B-cell lymphoma (DLBCL)MedDRA version: 20.0Level: LLTClassification code 10012820Term: Diffuse large B-cell lymphoma NOSSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000004864

EUCTR2015-004741-54-ITSEATTLE GENETICS, INC.50